Contribute Try STAT+ Today

Politicians have heaped fire and brimstone upon pharmaceutical companies for increasing the price of their products, some of which were approved decades ago. But far less ire has been directed at price tags on newly approved treatments — many of which continue to rise.

New cancer drugs cost about 17 times more than they did 40 years ago, according to Kaiser Health News, and a drug for spinal muscular atrophy approved in 2016 is one of the most expensive products on the market, the Boston Globe reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
    • What comment are you alleging that we blocked? The only one in our system by bpmanzoli – other than this one – is the comment you posted a minute earlier (“perhaps there is a cure for cancer and the legal drug cartels are just playing it to make as much money as they can of course legally”), which is live on the site.

      Pat Skerrett

  • perhaps there is a cure for cancer and the legal drug cartels are just playing it to make as much money as they can of course legally

  • It is no secret that there are revolving doors from the big pharmaceutical companies and the FDA. It is time to legalize all drugs, and I mean all, move all drugs to over the counter status. Allow for a commercial, more than one, pharmaceutical police force to do their own testing on any and all medications, and then tell the world the truth about side effects, good points and bad points. There are three kinds of Physicians, see study,
    1. Coasters 50%, these doctors study in college and in post grad and get all the knowledge they can, and then they coast until retirement, practicing health care that they learned in those first 10 years, never to learn much new info after.
    2. Boxers 35%, boxers read their 6 journals that are sent to their door, and they keep up to date with their speciality, their collegues and pat each other on the back, and they perpetuate the myth that their society authorities preach.
    3. SEEKERS 15%, These are physicians that cannot get enough information, they want to learn cures, they want the best for their patients, they read journals from across the world, they keep up, they read BIO MED CENTRAL, and they do their own patient research, they want to know their own patient outcomes.

    The Coasters and The Boxers do all they can to down play the seekers, for the Seekers are finding cures and doing great for the patients.

    For example, 2years ago ROSACEA was found to have a cure, Ivermectin, it was discovered in Kenya and India nearly the same time. Many papers have been written, yet, in the U.S. it is the rare dermatologist that knows about it, why, because it was discovered out of the US, not made here, and the US Boxer Journals will not print an article on it, “To Hell with the patients that need cures” Say the Coasters and Boxers.

    • in all careers 15-20% carry the rest. However in medicine like in politics there is a great deal of corruption.

    • I prefer the following:
      1) the top 15% in their class (seekers) make the best academics.

      2) the middle 65% class rank make the best clinicians, who dropped their NEJM subscriptions cause mostly information for the above 15%.

      3) the bottom 20% class rank make THE MOST MONEY, catching up on throwaway journals while in the loo.

      Remember the old joke about what do they call the guy who finishes dead last in medical school rank: DOCTOR!!!

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy